Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.260
-0.010 (-0.79%)
Jul 29, 2026, 4:00 PM EDT - Market closed
Akebia Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 232.4 | 236.2 | 160.18 | 194.62 | 292.48 | 211.65 | |
Revenue Growth | 25.69% | 47.46% | -17.70% | -33.46% | 38.19% | -28.17% |
Cost of Revenue | 44.13 | 39.46 | 63.18 | 74.15 | 85.57 | 150.67 |
Gross Profit | 188.28 | 196.73 | 97 | 120.47 | 206.92 | 60.98 |
Selling, General & Admin | 112.17 | 107.48 | 106.55 | 100.23 | 138.6 | 174.14 |
Research & Development | 67.41 | 62.36 | 37.65 | 63.08 | 129.99 | 147.85 |
Other Operating Expenses | 3.4 | 3.4 | 3.28 | 3.42 | 19.11 | 3.49 |
Total Operating Expenses | 182.99 | 173.24 | 147.48 | 166.73 | 287.7 | 325.48 |
Operating Income | 5.29 | 23.5 | -50.47 | -46.26 | -80.78 | -264.5 |
Interest Expense | -21.1 | -24.18 | -18.19 | -6.03 | -15.69 | - |
Other Non-Operating Income (Expense) | -2.84 | -3.04 | -0.75 | 0.36 | 2.24 | -17.52 |
Total Non-Operating Income (Expense) | -23.94 | -27.22 | -18.94 | -5.67 | -13.45 | -17.52 |
Pretax Income | -18.76 | -3.72 | -69.41 | -51.93 | -94.23 | -282.02 |
Provision for Income Taxes | - | 1.62 | - | - | - | - |
Net Income | -8.27 | -5.35 | -69.41 | -51.93 | -94.23 | -282.02 |
Net Income to Common | -8.27 | -5.35 | -69.41 | -51.93 | -94.23 | -282.02 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 265 | 257 | 211 | 187 | 183 | 166 |
Shares Outstanding (Diluted) | 269 | 257 | 211 | 187 | 183 | 166 |
Shares Change | 22.44% | 21.91% | 12.53% | 2.56% | 10.14% | 19.85% |
EPS (Basic) | -0.08 | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
EPS (Diluted) | -0.08 | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 60.04 | 67.7 | -40.69 | -23.38 | -73.27 | -253.02 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | 0.22 | 0.26 | -0.19 | -0.12 | -0.40 | -1.52 |
Gross Margin | 81.01% | 83.29% | 60.56% | 61.90% | 70.74% | 28.81% |
Operating Margin | 2.28% | 9.95% | -31.51% | -23.77% | -27.62% | -124.97% |
Profit Margin | -3.56% | -2.26% | -43.33% | -26.68% | -32.22% | -133.25% |
FCF Margin | 25.83% | 28.66% | -25.40% | -12.02% | -25.05% | -119.55% |
EBITDA | 6.57 | 24.77 | -12.97 | -8.63 | -43.08 | -226.53 |
EBITDA Margin | 2.83% | 10.49% | -8.10% | -4.43% | -14.73% | -107.03% |
EBIT | 5.29 | 23.5 | -50.47 | -46.26 | -80.78 | -264.5 |
EBIT Margin | 2.28% | 9.95% | -31.51% | -23.77% | -27.62% | -124.97% |
Effective Tax Rate | - | -43.64% | 0.00% | 0.00% | 0.00% | 0.00% |